

# Jian-Gao Fan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1169708/publications.pdf>

Version: 2024-02-01

71  
papers

6,962  
citations

172457

29  
h-index

88630

70  
g-index

80  
all docs

80  
docs citations

80  
times ranked

7805  
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
2	New trends on obesity and NAFLD in Asia. <i>Journal of Hepatology</i> , 2017, 67, 862-873.	3.7	759
3	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	3.7	734
4	Epidemiology of non-alcoholic fatty liver disease in China. <i>Journal of Hepatology</i> , 2009, 50, 204-210.	3.7	444
5	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	4.2	422
6	Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. <i>Journal of Digestive Diseases</i> , 2011, 12, 38-44.	1.5	227
7	Lipotoxic Hepatocyte-Derived Exosomal MicroRNA 192a <sup>5p</sup> Activates Macrophages Through Rictor/Akt/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 72, 454-469.	7.3	170
8	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	8.1	135
9	Role of diet and nutritional management in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 81-87.	2.8	127
10	Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). <i>Journal of Digestive Diseases</i> , 2019, 20, 163-173.	1.5	111
11	Post-translational regulation of lipogenesis via AMPK-dependent phosphorylation of insulin-induced gene. <i>Nature Communications</i> , 2019, 10, 623.	12.8	95
12	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 4702.	3.3	92
13	Î2-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/Î2-catenin signaling inhibits hepatic stellate cell activation. <i>Molecular Medicine Reports</i> , 2014, 9, 2145-2151.	2.4	86
14	Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2015, 16, 5161-5179.	4.1	81
15	circRNA_0046367 Prevents Hepatotoxicity of Lipid Peroxidation: An Inhibitory Role against Hepatic Steatosis. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-16.	4.0	77
16	Hepatic Steatosis Is Highly Prevalent in Hepatitis B Patients and Negatively Associated with Virological Factors. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2571-2579.	2.3	74
17	circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling. <i>World Journal of Gastroenterology</i> , 2018, 24, 323-337.	3.3	72
18	Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. <i>Liver International</i> , 2015, 35, 2392-2400.	3.9	71

#	ARTICLE	IF	CITATIONS
19	NAFLD leads to liver cancer: Do we have sufficient evidence?. <i>Cancer Letters</i> , 2014, 345, 230-234.	7.2	54
20	Circular RNA Profiling and Bioinformatic Modeling Identify Its Regulatory Role in Hepatic Steatosis. <i>BioMed Research International</i> , 2017, 2017, 1-13.	1.9	50
21	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	4.4	49
22	Commonly used animal models of non-alcoholic steatohepatitis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2009, 8, 233-40.	1.3	47
23	Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. <i>Translational Research</i> , 2017, 180, 103-117.e4.	5.0	46
24	Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. <i>Archives of Iranian Medicine</i> , 2016, 19, 197-203.	0.6	45
25	Prevalence of and Risk Factors for Type 2 Diabetes Mellitus in Hyperlipidemia in China. <i>Medical Science Monitor</i> , 2015, 21, 2476-2484.	1.1	40
26	Prevention of hepatocellular carcinoma in nonviral-related liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 712-719.	2.8	35
27	Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 93-102.	3.7	35
28	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	4.4	35
29	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. <i>PLoS ONE</i> , 2016, 11, e0155934.	2.5	34
30	Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1792-1804.	3.3	34
31	Unhealthy lifestyle habits and physical inactivity among Asian patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	3.9	32
32	Saturated Fatty Acid Inhibits Viral Replication in Chronic Hepatitis B Virus Infection With Nonalcoholic Fatty Liver Disease by Toll-Like Receptor 4-Mediated Innate Immune Response. <i>Hepatitis Monthly</i> , 2015, 15, e27909.	0.2	30
33	Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. <i>Scientific Reports</i> , 2015, 5, 13980.	3.3	29
34	High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2014, 14, 195.	2.0	25
35	What are the clinical settings and outcomes of lean NAFLD?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 289-290.	17.8	24
36	Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 154-161.	1.3	24

#	ARTICLE	IF	CITATIONS
37	APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2284-2293.	2.3	22
38	The gut microbiome: a novel player in chronic liver diseases. <i>Journal of Gastroenterology</i> , 2021, 56, 1-11.	5.1	22
39	Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00323.	2.5	22
40	Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2015, 21, 8605.	3.3	21
41	Thyroid function is associated with nonalcoholic fatty liver disease in chronic hepatitis B-infected subjects. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1753-1758.	2.8	20
42	Acute Hepatitis of Unknown Origin in Children: Early Observations from the 2022 Outbreak. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 522-530.	1.4	19
43	Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B. <i>Scientific Reports</i> , 2017, 7, 10517.	3.3	18
44	Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic. <i>Current Cancer Drug Targets</i> , 2017, 17, 505-511.	1.6	17
45	Fuzheng Huayu Recipe Ameliorates Liver Fibrosis by Restoring Balance between Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Hepatic Stellate Cells. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	16
46	Guidelines of prevention and treatment for alcoholic liver disease (2018, China). <i>Journal of Digestive Diseases</i> , 2019, 20, 174-180.	1.5	16
47	RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 1085-92.	0.5	14
48	Comparison of real-time contrast-enhanced ultrasonography and standard ultrasonography in liver cancer microwave ablation. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 1345-1348.	1.8	12
49	Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease. <i>International Journal of Molecular Medicine</i> , 2018, 42, 443-452.	4.0	12
50	Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR- $\beta$ . <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 780-786.	1.8	11
51	Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer. <i>Medicine (United States)</i> , 2019, 98, e17098.	1.0	10
52	Regulation of adipokines by polyunsaturated fatty acids in a rat model of non-alcoholic steatohepatitis. <i>Archives of Iranian Medicine</i> , 2014, 17, 563-8.	0.6	10
53	Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 941-953.	6.1	9
54	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. <i>World Journal of Gastroenterology</i> , 2020, 26, 2416-2426.	3.3	9

#	ARTICLE	IF	CITATIONS
55	The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. <i>Oncology Letters</i> , 2016, 12, 951-955.	1.8	8
56	Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high-fat, high-cholesterol diet. <i>Journal of Digestive Diseases</i> , 2020, 21, 179-188.	1.5	7
57	Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in Hepatology Research. <i>Current Stem Cell Research and Therapy</i> , 2015, 10, 208-215.	1.3	7
58	APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2020, 2020, 1-9.	1.9	6
59	Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. <i>Journal of Digestive Diseases</i> , 2020, 21, 604-609.	1.5	5
60	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	2.8	5
61	Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring. <i>World Journal of Gastroenterology</i> , 2022, 28, 1681-1691.	3.3	5
62	PNPLA3rs1010023 Predisposes Chronic Hepatitis B to Hepatic Steatosis but Improves Insulin Resistance and Glucose Metabolism. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-12.	2.3	4
63	Fibroblast Growth Factor 19 in Gestational Diabetes Mellitus and Fetal Growth. <i>Frontiers in Endocrinology</i> , 2021, 12, 805722.	3.5	4
64	Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 1-3.	1.3	2
65	Efficacy of Intra-gastric Balloons in the Markers of Metabolic Dysfunction-associated Fatty Liver Disease: Results from Meta-analyses. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	2
66	Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 473-477.	8.9	2
67	Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 334-335.	3.7	1
68	Multidisciplinary participation: the key to cure for non-alcoholic fatty liver disease. <i>Journal of Digestive Diseases</i> , 2021, .	1.5	1
69	Editorial: opposite effects of genetic polymorphisms known to induce <sc>NAFLD</sc> on hepatic and cardiovascular outcomes in Chinese population. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 876-877.	3.7	1
70	A tribute to Dr Guang-bi Yao (1931-2010). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1027-1028.	2.8	0
71	Letter: moderate-to-severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 617-618.	3.7	0